Comparative Pharmacology
Head-to-head clinical analysis: CEFUROXIME AXETIL versus MONOCID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFUROXIME AXETIL versus MONOCID.
CEFUROXIME AXETIL vs MONOCID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefuroxime axetil is a prodrug that is hydrolyzed to cefuroxime, a second-generation cephalosporin antibiotic. It inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and disrupting peptidoglycan cross-linking.
Cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
250–500 mg orally twice daily; for severe infections (e.g., pneumonia), 500 mg twice daily; for uncomplicated urinary tract infections, 250 mg twice daily; for Lyme disease, 500 mg twice daily for 20 days.
1 g intramuscularly or intravenously every 24 hours; for severe infections, 2 g every 24 hours.
None Documented
None Documented
1.2-1.6 hours (normal renal function); prolonged to 15-22 hours in end-stage renal disease (CrCl <10 mL/min). For oral cefuroxime axetil, consider absorption and conversion to active cefuroxime.
Terminal elimination half-life: 4-5 hours (prolonged to 12-24 hours in severe renal impairment; dosing adjustment recommended for CrCl <50 mL/min).
Renal: 70-90% unchanged by glomerular filtration and tubular secretion; biliary/fecal: <10%
Renal: ~90% unchanged in urine via glomerular filtration and tubular secretion; biliary/fecal: ~5% (cefonicid undergoes minimal hepatic metabolism; ~4% excreted in feces as parent drug and metabolites).
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic